Graffinity and Boehringer Ingelheim Enter into Drug Discovery Research Agreement

Graffinity Pharmaceuticals GmbH has announced that it has entered into a research collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. which involves four global research sites of Boehringer Ingelheim.

Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of various small molecule hit series against multiple drug targets.

Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify and evolve small molecule hit structures focusing on compounds with novel modes of action.

Mathias Woker, Senior Vice President of Business Development of Graffinity, stated, "This collaboration demonstrates again that Graffinity's fragment based drug discovery technology is one of the most important and reliable alternatives to standard approaches of identifying NCEs."

"When leading companies, such as Boehringer Ingelheim, choose to work with us, they know that they significantly increase their chances of finding truly novel, efficacious and safe small molecules - in particular since they are accessing one of the largest fragment libraries available today with about 20,000 fragments and 90,000 lead-like structures."

"They also know that, given these strongly improved odds in their favor, they effectively save money and valuable time in drug discovery."

"Our fragment based drug discovery platform and process are uniquely suited for challenging drug targets, since our drug fragment libraries, together with the proprietary label- and assay-free high-throughput imaging technology, allow us to generate quality hit structures for both known as well as novel modes of action - thus exploiting completely new avenues in chemical diversity space."